In cases like this, where the drug being tested (Velcade) received FDA approval while the given trial was in progress, the data-monitoring board must be under intense pressure to end the control arm for fear that the control-arm patients would drop out (and get Velcade on their own) if not offered the opportunity to cross over.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.